LABT Financials

Income Statement
MetricQ3 2026Q2 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
1.5M
-60.1%
3.8M
R&D
733.1K
+45.7%
503.0K
SG&A
776.5K
-76.4%
3.3M
Operating Income
-1510731
+60.1%
-3789660
EBITDA
-1509572
+60.2%
-3788502
Net Income
-1474731
+60.9%
-3772008
EPS (Basic)
$-0.62
+77.5%
$-2.75
EPS (Diluted)
$-0.62
+77.5%
$-2.75
Shares (Diluted)
2.4M
+68.1%
1.4M
Lakewood-Amedex Biotherapeutics (LABT) — Financials